ADJUVANT CHEMOTHERAPY OF STAGE-II NONSEMINOMATOUS TESTICULAR CANCER

85 patients with resected stage II non-seminomatous testicular cancer were treated with adjuvant cisplatin-based chemotherapy. Only one pati ent developed a relapse 14 months after discontinuation of adjuvant ch emotherapy, which was successfully treated with salvage chemotherapy. One patient developed a contralateral testicular tumor 6 years after p rimary therapy. After a median observation time of 6 years (range 2 mo nths to 13 years) 84 patients are alive without evidence of testicular cancer; one died from an unrelated cause. In conclusion, adjuvant cis platin-based chemotherapy for resected stage Il nonseminomatous testic ular cancer almost always prevents relapse.